Opinion

Video

Novel Nonstatin LLTs for Lowering LDL-C and CVD Risk

Key Takeaways

  • Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
  • Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
SHOW MORE

Panelists discuss how newer nonstatin therapies, such as PCSK9 inhibitors (inclisiran, alirocumab, evolocumab) and bempedoic acid, offer additional options for LDL-C reduction and cardiovascular risk management.

Related Videos
Safety Profile, Accessibility of Tapinarof Cream for Atopic Dermatitis, with Adelaide Hebert, MD
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
Sobia Laique, MD | Credit: Cleveland Clinic
Sobia Laique, MD | Credit: Cleveland Clinic
What is the Global Lung Function Initiative and Its Purpose for Lung Function Testing?
Greg A. Sachs, MD I Credit: Regenstrief Institute
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.